BioSpace News Archive

Horizon Therapeutics plc announced the European Commission approval of UPLIZNA® as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 immunoglobulin G seropositive, following the positive opinion adopted by the Committee for Medicinal Products for Human Use of the European Medicines Agency on 11th November, 2021.

aTyr Pharma, Inc. announced that it will report first quarter 2022 financial results and provide a corporate update after the market close on Monday, May 9, 2022.

Mersana Therapeutics, Inc. announced that it will provide business updates and report financial results for the first quarter ended March 31, 2022 on Monday, May 9, 2022 and will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.

Rancho Biosciences is pleased to announce the launch of its Single Cell Data Science (SCDS) pre-competitive consortium.

Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today a poster featuring topline data from the EU study of the Pure-Vu System has been selected to be presented at Digestive Disease Week® (DDW).

Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited (EVL) acquired six development-stage, ready-to-use injectable product candidates from Nevakar Injectables Inc., a subsidiary of Nevakar, Inc.

BioVaxys Technology Corp.,, announced that it has continued to expand the patent coverage for its cancer vaccine platform by filing an international patent application through the Patent Cooperation Treaty for broad geographic market coverage outside the US for cervical cancer.

Limaca Medical ( “Limaca” ) announced today that its Precision-GI™ Endoscopic Ultrasound Biopsy Product has received a Breakthrough Device Designation from the U.S. Food and Drug Administration ( “FDA” ).

Altavant Sciences announced today that the company made an oral presentation of preclinical results supporting the development of ALTA-2530 for the treatment of bronchiolitis obliterans syndrome.

Aethlon Medical, Inc. (Nasdaq: AEMD), today announced the publication of a pre-print manuscript featuring data that demonstrated Aethlon’s proprietary GNA affinity resin was able to bind seven clinically relevant SARS-CoV-2 variants in vitro, including the Delta and Omicron variants.